L. McFarlane

发表

Enhanced immune responses following heterologous vaccination with self-amplifying RNA and mRNA COVID-19 vaccines

A. Winston, R. Shattock, J. Harker, 2022, PLoS Pathogens.

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens

R. Sanders, R. Shattock, B. Asquith, 2022, Frontiers in Immunology.

Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens

Q. Sattentau, A. Ward, R. Sanders, 2021, bioRxiv.

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

P. Andersen, R. Shattock, K. Korsholm, 2019, The Lancet. Infectious diseases.

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

S. McCormack, V. Libri, A. Winston, 2021, eClinicalMedicine.

The Plasmodium berghei Ca2+/H+ Exchanger, PbCAX, Is Essential for Tolerance to Environmental Ca2+ during Sexual Development

J. Pittman, R. Tewari, S. Krishna, 2013, PLoS pathogens.

Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine

S. McCormack, S. Kent, P. McKay, 2018, Human gene therapy.

COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

S. McCormack, V. Libri, A. Winston, 2023, eClinicalMedicine.

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial

S. McCormack, V. Libri, A. Winston, 2022, eClinicalMedicine.